XILIO DEVELOPMENT INC
NASDAQ: XLO (Xilio Therapeutics, Inc.)
Last update: 28 minutes ago8.93
-0.06 (-0.72%)
| Previous Close | 9.00 |
| Volume | 4,841 |
| Price / Sales | 2.00 |
| Price / Book | 0.820 |
| 52 Weeks Range |
| Operating Margin (TTM) | -472.73% |
| Diluted EPS (TTM) | -0.650 |
| Total Debt/Equity (MRQ) | 73.50% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 21.10 M |
| Levered Free Cash Flow (TTM) | 19.13 M |
| Return on Assets (TTM) | -38.21% |
| Return on Equity (TTM) | -297.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Xilio Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.07 |
|
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 45.76% |
| % Held by Institutions | 22.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2026 | 664,021 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 650,389 |
| Orbimed Advisors Llc | 30 Jun 2026 | 592,300 |
| Frazier Life Sciences Management, L.P. | 30 Jun 2026 | 422,505 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 225,994 |
| Vanguard Capital Management Llc | 30 Jun 2026 | 178,517 |
| Sio Capital Management, Llc | 30 Jun 2026 | 152,464 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 111,541 |
| Merck & Co., Inc. | 30 Jun 2026 | 105,982 |
| Vanguard Group Inc | 31 Dec 2025 | 89,694 |
| Renaissance Technologies Llc | 30 Jun 2026 | 64,153 |
| Morgan Stanley | 30 Jun 2026 | 56,954 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2026 | 47,695 |
| Geode Capital Management, Llc | 30 Jun 2026 | 39,055 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |